We’re proud to be part of such a tight-knit community. The more we can stay in touch, the closer we can work together. Click subscribe to receive news and updates about Amylyx.
Preclinical Development of AMX0114, an Antisense Oligonucleotide Targeting Calpain-2
Lead Author: Evan Mizerak (Presenter)
Published: Oligonucleotides for CNS Summit
Date: July 10, 2024
Learnings from the CENTAUR and PHOENIX Trials: Biomarker Results
Lead Author: Sabrina Paganoni, MD, PhD (Presenter)
Published: European Network to Cure ALS (ENCALS) Meeting 2024
Date: June 17 - 20, 2024
Results From the Global Phase 3 Trial Evaluating Sodium Phenylbutyrate and Ursodoxicoltaurine in ALS
Lead Author: Leonard H. van den Berg, MD, PhD, and Sabrina Paganoni, MD, PhD (Presenters)
Published: European Network to Cure ALS (ENCALS) Meeting 2024
Date: June 17 - 20, 2024
Updates on Development of AMX0114: An Antisense Oligonucleotide Inhibitor of Calpain-2, a Critical Effector of Axonal Degeneration
Lead Author: Lauren Kett, MD, PhD (Presenter)
Published: European Network to Cure ALS (ENCALS) Meeting 2024
Date: June 17 - 20, 2024
Understanding Treatment Barriers and Adherence Among People Living with Amyotrophic Lateral Sclerosis in Real World Clinical Practice
Lead Author: Genevieve Matte, MDCM, FRCP (Presenter)
Published: 2024 Canadian Neurological Sciences Federation (CNSF) Congress
Date: May 20 - 26, 2024
Assessment of AMX0114, An Antisense Oligonucleotide Targeting Calpain-2, in Multiple Models of Axonal Degeneration
Lead Author: Evan Mizerak (Presenter)
Published: TIDES USA | Oligonucleotide & Peptide Therapeutics
Date: May 14 - 17, 2024
Results From a Global Phase 3 Trial Evaluating an Oral, Fixed-Dose Combination of Sodium Phenylbutyrate and Taurursodiol in Amyotrophic Lateral Sclerosis
Lead Author: Leonard H van den Berg, MD, PhD (Presenter)
Published: American Academy of Neurology Annual Meeting 2024
Date: April 13 - 18, 2024
ORION: A Global, Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial of AMX0035 in Progressive Supranuclear Palsy
Lead Author: Günter Höglinger, MD (Presenter)
Published: AD/PD 2024 International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD)
Date: March 5 - 9, 2024
Findings From a Pharmacokinetic and Pharmacodynamic Study of Sodium Phenylbutyrate and Taurursodiol in Participants With Amyotrophic Lateral Sclerosis
Lead Author: James Wymer, MD (Presenter)
Published: 2024 MDA Clinical & Scientific Conference (MDA)
Date: March 3 - 6, 2024
Next Steps in Development for AMX0114: An Antisense Oligonucleotide Targeting Calpain-2, a Critical Effector of Axonal Degeneration
Lead Author: Joshua Cohen
Published: 2024 MDA Clinical & Scientific Conference (MDA)
Date: March 3 - 6, 2024